AQR Capital Management LLC Has $272.21 Million Stake in Gilead Sciences, Inc. $GILD

AQR Capital Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,470,838 shares of the biopharmaceutical company’s stock after buying an additional 606,168 shares during the period. AQR Capital Management LLC owned 0.20% of Gilead Sciences worth $272,212,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of GILD. Activest Wealth Management raised its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. GoalVest Advisory LLC raised its stake in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences during the second quarter valued at $27,000. Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences in the 2nd quarter worth about $30,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the transaction, the insider owned 107,193 shares of the company’s stock, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kelly A. Kramer sold 2,806 shares of the stock in a transaction on Wednesday, November 26th. The stock was sold at an average price of $127.11, for a total value of $356,670.66. Following the transaction, the director owned 1,339 shares in the company, valued at $170,200.29. The trade was a 67.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 135,757 shares of company stock worth $16,616,127 in the last three months. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of several analyst reports. Daiwa Capital Markets lifted their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Mizuho upped their price target on Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $131.13.

Gilead Sciences Trading Down 2.3%

NASDAQ:GILD opened at $120.40 on Friday. The business has a 50 day moving average price of $121.89 and a two-hundred day moving average price of $115.71. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a market cap of $149.38 billion, a P/E ratio of 18.67, a price-to-earnings-growth ratio of 0.68 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.